Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Phase II Study Evaluating Efficacy, Safety and Pharmacokinetics of Pasireotide in Patients With Dumping Syndrome

Phase 2

Completed

Conditions: Dumping Syndrome

Interventions: Drug: SOM230

First Posted Date: 2012-07-11

Last Posted Date: 2017-05-10

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 43

Registration Number: NCT01637272

Locations: 🇺🇸
Virginia Endocrinology Research SC, Chesapeake, Virginia, United States
🇺🇸
Montefiore Medical Center CLCZ696B2320, Bronx, New York, United States
🇳🇱
Novartis Investigative Site, Utrecht, Netherlands

and more 4 locations

Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)

Phase 3

Completed

Conditions: Plaque-type Psoriasis

Interventions: Drug: Secukinumab 300mg
Drug: Placebo
Drug: Secukinumab 150mg

First Posted Date: 2012-07-10

Last Posted Date: 2018-09-27

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 182

Registration Number: NCT01636687

Locations: 🇩🇪
Novartis Investigative Site, Tuebingen, Germany

Efficacy and Safety of QMF149 vs. Salmeterol Xinafoate/Fluticasone Propionate in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Phase 2

Completed

Conditions: COPD

Interventions: Drug: QMF149
Drug: Salmeterol

First Posted Date: 2012-07-10

Last Posted Date: 2014-11-17

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 629

Registration Number: NCT01636076

Locations: 🇹🇭
Novartis Investigative Site, Songkla, Thailand

Phase Ib of Abiraterone Acetate Plus BEZ235 or BKM120 in Castration-resistant Prostate Cancer (CRPC) Patients

Phase 1

Completed

Conditions: Castration-resistant Prostate Cancer

Interventions: Drug: BEZ235
Drug: BKM120

First Posted Date: 2012-07-06

Last Posted Date: 2020-12-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 43

Registration Number: NCT01634061

Locations: 🇺🇸
Cedars Sinai Medical Center SC, Los Angeles, California, United States
🇺🇸
Hackensack University Medical Center Hackensack Univ, Hackensack, New Jersey, United States
🇬🇧
Novartis Investigative Site, Sutton, United Kingdom

Study of Safety and Preliminary Efficacy for LDK378 in Japanese Patients With Genetic Alterations in Anaplastic Lymphoma Kinase (ALK)

Phase 1

Completed

Conditions: Tumors Characterized by Genetic Alterations in Anaplastic Lymphoma Kinase (ALK)

Interventions: Drug: LDK378

First Posted Date: 2012-07-06

Last Posted Date: 2020-12-19

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 22

Registration Number: NCT01634763

Locations: 🇯🇵
Novartis Investigative Site, Fukuoka, Japan

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Phase 3

Terminated

Conditions: Relapsing-remitting Multiple Sclerosis (RRMS)

Interventions: Drug: glatiramer acetate
Drug: fingolimod

First Posted Date: 2012-07-04

Last Posted Date: 2019-05-28

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 1064

Registration Number: NCT01633112

Locations: 🇵🇷
Novartis Investigative Site, Guaynabo, Puerto Rico

A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi

Phase 3

Terminated

Conditions: Metastatic Breast Cancer

Interventions: Drug: Fulvestrant
Drug: BKM120
Drug: BKM120 matching placebo

First Posted Date: 2012-07-04

Last Posted Date: 2019-01-30

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 432

Registration Number: NCT01633060

Locations: 🇺🇸
University of Maryland Medical Center Univ Maryland, Baltimore, Maryland, United States
🇺🇸
The Methodist Hospital Cancer Center, Houston, Texas, United States
🇺🇸
Los Angeles Hematology/Oncology Medical Group Onc Dept., Los Angeles, California, United States

and more 35 locations

Safety and Pharmacokinetis of TAP311 in Dyslipidemic Patients

Phase 1

Completed

Conditions: Dyslipidaemia

Interventions: Drug: TAP311 capsules
Drug: Placebo

First Posted Date: 2012-07-02

Last Posted Date: 2013-12-02

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 279

Registration Number: NCT01632358

Locations: 🇨🇳
Novartis Investigative Site, Taichung, Taiwan

Evaluation of the Metabolic Effects of LCZ696 and Amlodipine in Obese Hypertensive Subjects

Phase 2

Completed

Conditions: Hypertension
Concurrent Obesity

Interventions: Drug: LCZ696
Drug: amlodipine
Drug: Placebo

First Posted Date: 2012-06-29

Last Posted Date: 2015-08-10

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 98

Registration Number: NCT01631864

Locations: 🇳🇱
Novartis Investigative Site, Maastricht, Netherlands

Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors

Phase 2

Terminated

Conditions: Pancreatic Neuroendocrine Tumors (pNET)

Interventions: Drug: BEZ235
Drug: Everolimus

First Posted Date: 2012-06-27

Last Posted Date: 2016-04-07

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 62

Registration Number: NCT01628913

Locations: 🇺🇸
Cedars Sinai Medical Center SC-3, Los Angeles, California, United States
🇺🇸
Montefiore Medical Center SC, Bronx, New York, United States
🇺🇸
University of Colorado Univ Colorado, Aurora, Colorado, United States

and more 2 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy